3rd Jul 2020 18:34
Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics company - Partners with the University of Michigan to extend the application of the KidneyIntelX platform to an expanded population of patients with established chronic kidney disease or at risk of developing of this disease. RenalytixAI also announces a data sharing agreement with an undisclosed pharmaceutical company, enabling investigation of repeat testing with KidneyIntelX and prediction of therapeutic response.
Current stock price: 558.80 pence
Year-to-date change: up 54%
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc